blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3344275

EP3344275 - PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.01.2024
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  03.02.2023
FormerGrant of patent is intended
Status updated on  19.09.2022
FormerExamination is in progress
Status updated on  03.04.2020
FormerRequest for examination was made
Status updated on  08.06.2018
FormerThe international publication has been made
Status updated on  11.03.2017
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): BE		published on 04.09.2024 [2024/36]
Applicant(s)For all designated states
Aileron Therapeutics, Inc.
285 Summer Street, Unit 101
Boston, MA 02210 / US
[2023/12]
Former [2018/28]For all designated states
Aileron Therapeutics, Inc.
281 Albany Street
Cambridge, MA 02139 / US
Inventor(s)01 / AIVADO, Manuel
127 Magnolia Drive
Chester Springs, Pennsylvania 19425 / US
02 / GUERLAVAIS, Vincent
43 Kenliworth Road
Arlington, Massachusetts 02476 / US
03 / OLSON, Karen
174 Lakeview Avenue
Waltham, Massachusetts 02451 / US
 [2018/28]
Representative(s)Avidity IP
Broers Building
Hauser Forum
21 JJ Thomson Avenue
Cambridge CB3 0FA / GB
[2018/28]
Application number, filing date16843105.402.09.2016
[2018/28]
WO2016US50194
Priority number, dateUS201562214142P03.09.2015         Original published format: US 201562214142 P
US201662310254P18.03.2016         Original published format: US 201662310254 P
US201662344651P02.06.2016         Original published format: US 201662344651 P
US201662344791P02.06.2016         Original published format: US 201662344791 P
[2018/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017040990
Date:09.03.2017
Language:EN
[2017/10]
Type: A1 Application with search report 
No.:EP3344275
Date:11.07.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 09.03.2017 takes the place of the publication of the European patent application.
[2018/28]
Type: B1 Patent specification 
No.:EP3344275
Date:08.03.2023
Language:EN
[2023/10]
Type: B8 Corrected title page of specification 
No.:EP3344275
Date:12.04.2023
[2023/15]
Search report(s)International search report - published on:AU09.03.2017
(Supplementary) European search report - dispatched on:EP29.03.2019
ClassificationIPC:A61K31/337, A61K31/357, A61K31/7068, A61K38/12, A61K38/15, A61K38/21, A61K38/50, A61K45/06, A61P35/00, A61K31/436, A61K31/437, A61K31/44, A61K31/475, A61K31/506, A61K31/519, A61K31/553, A61K31/565, A61K31/573, A61K31/664, A61K31/706, A61K31/555
[2022/39]
CPC:
A61K38/08 (EP,KR,US); A61K38/12 (EP,KR,US); C07K7/56 (KR,US);
A61K31/337 (EP,KR,US); A61K31/357 (EP,US); A61K31/436 (EP,US);
A61K31/437 (EP,US); A61K31/44 (EP,US); A61K31/475 (EP,US);
A61K31/506 (EP,US); A61K31/519 (EP,US); A61K31/553 (EP,US);
A61K31/555 (EP,US); A61K31/565 (EP,US); A61K31/573 (EP,US);
A61K31/664 (EP,US); A61K31/706 (EP,US); A61K31/7068 (EP,KR,US);
A61K33/243 (EP,US); A61K38/15 (EP,KR,US); A61K38/21 (EP,KR,US);
A61K38/50 (EP,KR,US); A61K39/39558 (KR,US); A61K45/06 (EP,KR,US);
A61P35/00 (EP,KR); A61P35/02 (EP); A61P43/00 (EP);
C12Y305/01001 (EP,US); G01N33/5023 (US); A61K2300/00 (KR);
G01N2500/04 (US); G01N2500/10 (US) (-)
C-Set:
A61K31/337, A61K2300/00 (EP,US);
A61K31/357, A61K2300/00 (EP,US);
A61K31/44, A61K2300/00 (US,EP);
A61K31/555, A61K2300/00 (EP,US);
A61K31/7068, A61K2300/00 (EP,US);
A61K33/243, A61K2300/00 (EP,US);
A61K38/12, A61K2300/00 (US,EP);
A61K38/15, A61K2300/00 (US,EP);
A61K38/21, A61K2300/00 (US,EP);
A61K38/50, A61K2300/00 (US,EP)
(-)
Former IPC [2019/18]A61K38/12, A61K38/15, A61K38/21, A61K38/50, A61K31/7068, A61K31/337, A61K31/357, A61K45/06, A61P35/00
Former IPC [2018/28]A61K38/12, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/28]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PEPTIDOMIMETISCHE MAKROZYKLEN UND VERWENDUNGEN DAVON[2018/28]
English:PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF[2018/28]
French:MACROCYCLES PEPTIDOMIMÉTIQUES ET LEURS UTILISATIONS[2018/28]
Entry into regional phase16.03.2018National basic fee paid 
16.03.2018Search fee paid 
16.03.2018Designation fee(s) paid 
16.03.2018Examination fee paid 
Examination procedure16.03.2018Examination requested  [2018/28]
16.03.2018Date on which the examining division has become responsible
23.10.2019Amendment by applicant (claims and/or description)
07.04.2020Despatch of a communication from the examining division (Time limit: M04)
17.08.2020Reply to a communication from the examining division
10.12.2020Despatch of a communication from the examining division (Time limit: M04)
20.04.2021Reply to a communication from the examining division
20.09.2022Communication of intention to grant the patent
26.01.2023Fee for grant paid
26.01.2023Fee for publishing/printing paid
26.01.2023Receipt of the translation of the claim(s)
Opposition(s)11.12.2023No opposition filed within time limit [2024/07]
Fees paidRenewal fee
27.09.2018Renewal fee patent year 03
27.09.2019Renewal fee patent year 04
28.09.2020Renewal fee patent year 05
27.09.2021Renewal fee patent year 06
27.09.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE02.09.2023
LU02.09.2023
BE30.09.2023
CH30.09.2023
[2024/36]
Former [2024/34]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE02.09.2023
LU02.09.2023
CH30.09.2023
Former [2024/33]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE02.09.2023
LU02.09.2023
Former [2024/28]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU02.09.2023
Former [2024/26]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU02.09.2023
Former [2024/25]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU02.09.2023
Former [2024/10]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/50]AT08.03.2023
CZ08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/49]AT08.03.2023
CZ08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/48]AT08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/46]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/38]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/37]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/36]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
Former [2023/35]ES08.03.2023
HR08.03.2023
LT08.03.2023
RS08.03.2023
NO08.06.2023
Former [2023/34]ES08.03.2023
LT08.03.2023
RS08.03.2023
Former [2023/33]ES08.03.2023
LT08.03.2023
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[X]WO2012021874  (AILERON THERAPEUTICS INC [US], et al) [X] 1-56, 94-96, 214, 226 and 229-232 * abstract, pg 1 para 4 - pg 4 para 8, pg 43 para 130, claims *;
 [X]WO2012021875  (AILERON THERAPEUTICS INC [US], et al) [X] 1-56, 94-96, 214, 226 and 229-232 * abstract, pg 1 para 4 - pg 4 para 8, pg 48 para 138, claims *;
 [X]WO2012021876  (AILERON THERAPEUTICS INC [US], et al) [X] 1-56, 94-96, 214, 226 and 229-232 * abstract, pg 1 para 4 - pg 4 para 9, pg 32 para 105, claims *;
 [X]WO2013123266  (AILERON THERAPEUTICS INC [US], et al) [X] 1-56 and 64-232 * abstract, pg 1 para 3 - pg 9 para 25, pg 50 para 158, pg 63 Table 1, claims *;
 [PX]WO2016049355  (AILERON THERAPEUTICS INC [US]) [PX] 1-56 and 64-232 * abstract, pg 1 para 4 - pg 13 para 58, pg 82 Table 1, pg 159 para 319, pg 188 para 418 *;
 [PX]WO2016049359  (AILERON THERAPEUTICS INC [US]) [PX] 1-56 and 64-232 * abstract, pg 1 para 3 - pg 13 para 73, pg 65 para 252, pg 90 para 336 - pg 92 para 344, pg 95 Table 3 *;
 [E]WO2016154058  (AILERON THERAPEUTICS INC [US]) [E] 1-56 and 64-232* abstract, pg 2 para 4 - pg 23 para 92, pg 78 para 247, pg 109 para 325 - pg 112 para 334, pg 122 Table 3 *;
 [A]  - CHANG, Y. S. et al., "Stapled a-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy", Proceedings of the National Academy of Sciences, (20130000), vol. 110, no. 36, pages E3445 - E3454, XP 055333079 [A] 0 * whole document *
 [A]  - BROWN, C. J. et al., "Stapled peptides with improved potency and specificity that activate p53", ACS Chemical Biology., (20120000), vol. 8, no. 3, pages 506 - 512, XP 055139125 [A] 0 * whole document *
 [A]  - AL-LAZIKANI, B. et al., "Combinatorial drug therapy for cancer in the post- genomic era", Nature Biotechnology, (20120000), vol. 30, no. 7, pages 679 - 692, XP 055370881 [A] 0 * whole document *
 [A]  - LI, F. et al., "Molecular-targeted agents combination therapy for cancer: Developments and potentials", International Journal of Cancer., (20140000), vol. 134, no. 6, pages 1257 - 1269, XP055517584 [A] 0 * whole document *

DOI:   http://dx.doi.org/10.1002/ijc.28261
by applicantUS4683202
 US4683195
 US5364851
 US5446128
 US5811515
 US5824483
 US6713280
 US7192713
 US7202332
 WO2008121767
 WO2008156712
 US7521051
 WO2010027827
 WO2010077634
 US2011065915
 US7932397
 WO2011066342
 US8008449
 US2011245477
 US8354509
 WO2013019906
 US8383796
 WO2013123266
    - "SwissProt", Database accession no. Q7ZUW7
    - GRUBBS et al., Acc. Chem. Res., (19950000), vol. 28, pages 446 - 452
    - YU et al., Nature, (20110000), vol. 479, page 88
    - PERYSHKOV et al., J. Am. Chem. Soc., (20110000), vol. 133, page 20754
    - VAICKUS, L., Crit Rev. in Oncol./Hemotol., (19910000), vol. 11, pages 267 - 97
    - SCHAFMEISTER et al., J. Am. Chem. Soc., (20000000), vol. 122, pages 5891 - 5892
    - SCHAFMEISTERVERDINE, J. Am. Chem. Soc., (20050000), vol. 122, page 5891
    - WALENSKY et al., Science, (20040000), vol. 305, pages 1466 - 1470
    - MUSTAPA et al., J. Org. Chem., (20030000), vol. 68, pages 8193 - 8198
    - YANG et al., Bioorg. Med. Chem. Lett., (20040000), vol. 14, pages 1403 - 1406
    - SAIKI et al., Science, (19880000), vol. 239, page 487
    - COTTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, page 4397
    - SHENK et al., Proc. Natl. Acad. Sci. USA, (19750000), vol. 72, page 989
    - CARIELLO, Human Genetics, (19880000), vol. 42, page 726
    - YANG et al., Methods Enzymol., (19860000), vol. 130, page 208
    - ANNIS, D. A.NAZEF, N.CHUANG, C. C.SCOTT, M. P.NASH, H., "A General Technique to Rank Protein-Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures", M. J. Am. Chem. Soc., (20040000), vol. 126, doi:10.1021/ja048365x, pages 15495 - 15503, XP002461719

DOI:   http://dx.doi.org/10.1021/ja048365x
    - "ALIS: An Affinity Selection-Mass Spectrometry System for the Discovery and Characterization of Protein-Ligand Interactions", D. A. ANNISC.-C. CHUANGN. NAZEF, Methods and Principles in Medicinal Chemistry, Wiley-VCH, vol. 2007, pages 121 - 184
    - VAICKUS, Crit Rev. Oncol./Hemotol., (19910000), vol. 11, pages 267 - 97
    - HUTCHESON et al., Breast cancer Research, (20110000), vol. 13, page R29
    - CHEN et al., Mol. Cancer Res., (20130000), vol. 11, no. 10, pages 1269 - 78
    - WHO Drug Information, (20130000), vol. 27, no. 1, pages 161 - 162
    - THOMPSON, R. H. et al., PNAS, (20040000), vol. 101, no. 49, pages 17174 - 17179
    - THOMPSON, R. H. et al., Cancer Res., (20060000), vol. 66, pages 3381 - 3385
    - GADIOT, J. et al., Cancer, (20110000), vol. 117, pages 2192 - 2201
    - TAUBE, J. M. et al., Sci Transl Med, (20120000), vol. 4, page 127ra37
    - TOPLIAN, S. L. et al., New Eng. J Med., (20120000), vol. 366, no. 26, pages 2443 - 2454
    - J. SONNEMANN et al., Invest New Drugs, (20120000), vol. 30, pages 25 - 36
    - Clin. Cancer Res., (20150000), vol. 21, no. 13, pages 2905 - 10
    - SCHAFMEISTERVERDINE, J., Am. Chem. Soc., (20050000), vol. 122, page 5891
    - "The CCP4 Suite: Programs for Protein Crystallography", Acta Crystallogr, (19940000), vol. D50, pages 760 - 763
    - P.R. EVANS, Joint CCP4 and ESF-EACBM Newsletter, (19970000), vol. 33, pages 22 - 24
    - A.VAGINA. TEPLYAKOV., J. Appl. Cryst., (19970000), vol. 30, pages 1022 - 1025
    - G.M. POPOWICZA. CZAMAU. ROTHWEILERA. SZWAGIERCZAKM. KRAJEWSKIL. WEBERT.A. HOLAK, Cell Cycle, (20070000), vol. 6, pages 2386 - 2392
    - G.N. MURSHUDOVA.A. VAGINE.J. DODSON, Acta Crystallogr, (19970000), vol. D53, pages 240 - 255
    - CHOU et al., Advances in Enzyme Regulation, (19840000), vol. 22, pages 27 - 55
    - ZHANG et al., Am J Cancer Res., (20160000), vol. 6, pages 97 - 104
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.